SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

Home・Akcijų sąrašas・Vetoquinol SA

Vetoquinol SA

Uždarymo kaina

SektoriusSveikatos priežiūra

78.2 -0.51

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.7

Max

Pagrindiniai rodikliai
By Trading Economics
Pajamos	25M
Pardavimai	258M
P/E Sektoriaus vid.	15.039 57.833
Dividendų pajamingumas	1.14
Pelno marža	9.734
Darbuotojai	2,497
EBITDA	48M

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	1.14% 2.47%
Kitas uždarbis	2026-03-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	908M
Ankstesnė atidarymo kaina	78.71
Ankstesnė uždarymo kaina	78.2

Naujienos nuotaikos

By Acuity

50%

144 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

72.6 / 75.1 Palaikymas ir pasipriešinimas

Vetoquinol SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-23 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026-03-23 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026-03-23 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026-03-23 23:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-23 23:59; UTC

Rinkos pokalbiai

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026-03-23 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026-03-23 23:37; UTC

Rinkos pokalbiai

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026-03-23 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026-03-23 22:23; UTC

Rinkos pokalbiai

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026-03-23 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026-03-23 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026-03-23 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026-03-23 22:08; UTC

Rinkos pokalbiai

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026-03-23 21:10; UTC

Svarbiausios naujienos

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026-03-23 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai

Uždarbis

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Vetoquinol SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Vetoquinol SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

72.6 / 75.1Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

144 / 350 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.